Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that uses low amplitude direct currents to alter cortical excitability. With well-established safety and tolerability, tDCS has been found to have the potential to ameliorate symptoms such as depression and pain in a range of conditions as well as to enhance outcomes of cognitive and physical training. However, effects are cumulative, requiring treatments that can span weeks or months and frequent, repeated visits to the clinic. The cost in terms of time and travel is often prohibitive for many participants, and ultimately limits real-world access.
Introduction
tDCS is a relatively recent therapy that operates through the use of low amplitude (2.0 mA or less) direct current to modulate cortical excitability 1 . Hundreds of clinical trials have demonstrated tDCS to be safe and well-tolerated [2] [3] [4] . tDCS is easier to use, lower in cost, and better tolerated when compared to other methods such as transcranial magnetic stimulation (e.g., tDCS has not been associated with the development of seizures 5, 6 ). Multiple tDCS sessions are required for benefit, especially when administered with the goal of enhancing rehabilitation outcomes. [7] [8] [9] [10] It is not yet known how many tDCS sessions are necessary or optimal, but the effects are cumulative with little evidence that tDCS over a single session produces behaviorally meaningful changes. 2, 11 For example, studies of depression have found 30 or more sessions needed for full benefit in some participants. 12, 13 Multiple sessions are especially important when pairing tDCS with a behavioral therapy, which only occurs with rigorous repetition across many sessions.
14 For many patients and caregivers, traveling to the outpatient facility to receive repeated tDCS treatment sessions is a major obstacle in terms of time, cost and travel arrangements. This real-world limitation has resulted in studies with small sample sizes and without adequate power or design to draw conclusions that can lead to clinical use. 15 Remote tDCS delivery would allow for participation in study protocols from home or other locations, and reach those patients who otherwise would not have access to these trials. Further, it allows the possibility for testing "ondemand" application for indications such as epilepsy and migraines.
We have worked with a diverse group of clinical investigators interested in remotely-supervised tDCS to develop guidelines and standards for remotely-supervised tDCS delivery including specialized equipment and specific training requirements both for staff and study participants 16 . Here, we developed a protocol to follow these guidelines and test for feasibility in patients with multiple sclerosis (MS), a disorder where tDCS may be a useful tool for the management of its symptoms.
1. If contact quality falls below "moderate" provide instructions on how to improve it using the troubleshooting steps in 6.9. 2. Remind the participant to not to remove the headset until the seconds have fully counted down to zero and the device shuts off (confirmed with a beeping noise). 3. Instruct the participant to remove the headset when the device beeps. 4. Direct the participant to remove sponge pockets from the device and discard them. Syringes are one time use as well and should also be discarded. 5. Ensure that the participant stores the device and headset in the kit. 6. Remind the participant to safely store the laptop, device, and all materials for the next session.
End of Study Analyses
1. Assess each study participant using a participant tracker. This serves as a method of recording study compliance, adverse events, and session completion. At the end of study, review each participant's data to determine study success. For the purpose of this protocol, study success will be defined by 80% of participants having completed 80% of study sessions 24 . 2. Validate session success through records of daily session attendance, review of daily pain scales and before and after stimulation questionnaires for adverse events Please see Supplemental Code Files for sample questionnaire. Note: Validation that the 20 min of stimulation were fully delivered can be reviewed at study end. The study technician can access the device for completion codes as confirmation.
Representative Results
We have adapted this protocol for use in MS. We targeted the delivery of ten tDCS stimulation sessions delivered over two weeks. 9, 10 The first two sessions of the ten were in-person training sessions and the following eight were remotely supervised (Figure 3) . The second session consists of an environmental suitability assessment where study technicians visited the participant's home to confirm appropriate set-up.
To complete the following remotely-supervised sessions, participants were provided with the tDCS device specially-designed for remote use and a headset that was modified for ease of use to guide accurate electrode placement. A device kit was provided and included the device and headset, one-time use sponge pockets for electrodes and syringes filled with the measured amount of saline required for each sponge, with all items individually labeled by day and organized for ease of use. Electrodes were placed in the bilateral dorsolateral prefrontal cortex (DLPC) position with the anodal electrode placed on the left side. 10 This offers ease of reliable electrode placement, wide therapeutic applications.
9,10
Based on prior studies we targeted 1.5 mA for 20 min sessions. The protocol 9, 10 allowed for a current reduction to 1.0 mA at baseline if this improves overall subject tolerability.
Participants were given a study-provided laptop computer configured for the study, including the easily accessible instructional video and link for secure video conference connection with the study technician. The laptop also included a program for remote monitoring of all computer activity, and a program to remotely access the computer for technical support. Detailed manuals for operation were used by both the participant and study technician, and a binder for self-report measures was provided.
A total of n=20 MS participants have completed the study. Inclusion criteria specified an Expanded Disability Status Scale (EDSS) 25 * of 6.0 or below OR 6.5 or above with proxy to ensure minimal motor requirements to operate the device. Enrollment has been representative of a range of impairment in MS (motor impairment, cognitive impairment, or both). All 20 participants, n=4 with proxy, were successfully trained to self-apply a tDCS session and 192 total sessions were completed. As shown in Figure 4 , 40 of the192 sessions included training; the remaining 152 were exclusively remotely-supervised sessions. Of the remotely-supervised sessions, 100% were executed correctly with successfully placement of electrodes, device operation and well-tolerated delivery of stimulation.
Limitations of the technique
While our preliminary results support the feasibility of this protocol, the sample size is limited. As enrollment expands, analyses will be made for gaps in training, ways to streamline sessions, enhance the instructional video, and make the technique more accessible to those with motor impairment (i.e., adaptive mice for computer usage, sponge pocket/headset modification to further ease application). Some participants in the EDSS range below 6.5 (not requiring proxy), may still experience some difficulty in headset preparation and troubleshooting computer related issues. Furthermore, while this study recommends full remote monitoring of participants throughout all sessions, future studies may deem some participants sufficiently trained to operate the device without supervision for the entirety of a session.
Significance of the method with respect to existing methods
These initial results demonstrate the feasibility of our protocol for remotely-supervised tDCS delivery for clinical trials, following a set of guidelines and standards that must be employed to safely, and effectively administer tDCS under remote supervision. The protocol was designed to have a decision-tree series of checkpoints with "stop" criteria (section 2.5.1 above) that must be cleared in order to proceed at each step (see Figure 1 ). These checkpoints addressed tolerability (experiences of pain or adverse effects to the treatment) and compliance (timely session attendance and proper technique). For each session 1 through 10, participants completed brief adverse event reports before and after their sessions (with items derived from a list of the most common tDCS side-effects in previous trials). In addition, participants completed the selfreport measures to address tolerability (before and after the session) and can complete symptom inventories as well. This study is significant in that it establishes a technique to examine a therapy in MS with adequate power while also providing broader access to tDCS treatment.
Future applications of the technique
Once the method for remotely-supervised tDCS has been fully piloted in the MS population, a larger, randomized controlled trial can be initiated to target symptom management. Through the use of the instructional training materials and structure around daily participant interactions, remotely-supervised tDCS can be accessed by a wider range of patient populations and expand clinical study of the technique.
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